Updated on 2025/03/21

写真a

 
ANDO Yuichi
 
Organization
Nagoya University Hospital Clinical Oncology and Chemotherapy Professor
Graduate School
Graduate School of Medicine
Title
Professor
External link

Degree 1

  1. 医学博士 ( 1999.3   名古屋大学 ) 

Research Interests 1

  1. clinical oncology

Research Areas 1

  1. Others / Others  / 臨床腫瘍学

Research History 4

  1. Nagoya University   Professor

    2012.5

      More details

    Country:Japan

  2. Nagoya University

    2022.4

  3. Nagoya University

    2022.4

  4. Nagoya University   Nagoya University Hospital

    2018.8 - 2022.3

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences

    1996.4 - 1999.3

      More details

    Country: Japan

  2. Nagoya University   Faculty of Medicine

    1984.4 - 1990.3

      More details

    Country: Japan

Professional Memberships 7

  1. 日本臨床腫瘍学会   理事

  2. 日本癌学会   評議員

  3. 日本臨床薬理学会   理事

  4. 日本がん治療学会

  5. American Society of Clinical Oncology

▼display all

Awards 1

  1. 日本癌学会奨励賞

    2004  

     More details

    Country:Japan

 

Papers 124

  1. Consent in Pharmacogenetic Testing

    Ando, Y; Terada, T

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 41 ( 22 ) page: 3875 - +   2023.8

     More details

  2. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

    Ando, Y; Nishiyama, H; Shimodaira, H; Takano, N; Sakaida, E; Matsumoto, K; Nakanishi, K; Sakai, H; Tsukamoto, S; Komine, K; Yasuda, Y; Kato, T; Fujiwara, Y; Koyama, T; Kitamura, H; Kuwabara, T; Yonezawa, A; Okumura, Y; Yakushijin, K; Nozawa, K; Goto, H; Matsubara, T; Hoshino, J; Yanagita, M

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   Vol. 28 ( 10 ) page: 1315 - 1332   2023.10

     More details

  3. A nationwide, cross-sectional, web-based survey on healthcare providers' knowledge about, attitudes toward, and perceived barriers to adherence to clinical practice guidelines for anticancer drug therapy for older patients with cancer in Japan

    Matsuoka, A; Shimazu, T; Takahashi, M; Nagashima, F; Nishiyama, H; Fujimori, M; Ando, Y

    JOURNAL OF GERIATRIC ONCOLOGY   Vol. 14 ( 1 ) page: 101399   2023.1

     More details

  4. A rapid and durable response to larotrectinib in a patient with <i>NTRK</i> fusion-positive secretory carcinoma originating from the external auditory canal

    Ando, Y; Morita, S; Shimokata, T; Tsuzuki, T; Inafuku, S; Iwami, K; Brega, N; Akagawa, T; Tsujino, T; Ogawa, T

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 4 ) page: 242 - 246   2022.10

     More details

  5. Genomic profiles of patients with skin melanoma in the era of immune checkpoint inhibitors.

    Liang Y, Maeda O, Nishida K, Chretien B, Ando Y

    Cancer science     2025.1

     More details

    Language:English  

    DOI: 10.1111/cas.16338

    PubMed

▼display all

Books 3

  1. 高齢者のがん薬物療法ガイドライン

    統括委員長 安藤雄一

    編集:日本臨床腫瘍学会・日本癌治療学会  2019.7 

     More details

    Language:Japanese Book type:Scholarly book

  2. 治療学 内科学総論 内科学書

    安藤雄一( Role: Contributor)

    中山書店  2019 

     More details

    Language:Japanese

  3. 薬物動態・薬力学.新臨床腫瘍学 がん薬物療法専門医のために

    安藤雄一( Role: Contributor)

    南江堂  2018 

     More details

    Language:Japanese

KAKENHI (Grants-in-Aid for Scientific Research) 16

  1. 抗がん薬による下痢・腸炎の病態解明と新治療法の開発

    2017.4 - 2020.3

    科学研究費補助金  基盤研究(C)

  2. がん薬物療法におけるサルコペニアの臨床的意義

    2014.4 - 2017.3

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Principal investigator 

  3. Exploring biomarkers for immune checkpoint inhibitors in elderly patients with cancer

    Grant number:22K07415  2022.4 - 2025.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

  4. Study on proper use of oral anticoagulants combined with 5-fluorouracil

    Grant number:22K06743  2022.4 - 2025.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

  5. Exploratory analysis of DNA methylation as a novel biomarker in gastrointestinal cancer chemotherapy

    Grant number:20K08328  2020.4 - 2024.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Maeda Osamu

      More details

    Authorship:Coinvestigator(s) 

    DNA and RNA were extracted from tumor samples from esophageal and gastric cancers undergoing chemotherapy, and tumor-derived circulating DNA was extracted from blood samples. Comprehensive analysis of gene mutation, gene expression, and DNA methylation was performed. Methylation levels of blood-derived ctDNA before and after chemotherapy with cisplatin and fluorouracil for 185 genes whose DNA methylation was altered in the anti-cancer drug-resistant cell lines, SPTSSB increased and CD81 and FASTK decreased after chemotherapy, which were consistent with the changes seen in the anti-cancer drug-resistant cell lines. The changes were consistent with those seen in anticancer drug-resistant cell lines. The results suggest that changes in DNA methylation levels associated with anticancer drug resistance may also be detectable in ctDNA.

▼display all